MY127734A - Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer - Google Patents

Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Info

Publication number
MY127734A
MY127734A MYPI20012896A MYPI20012896A MY127734A MY 127734 A MY127734 A MY 127734A MY PI20012896 A MYPI20012896 A MY PI20012896A MY PI20012896 A MYPI20012896 A MY PI20012896A MY 127734 A MY127734 A MY 127734A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical compositions
farnesyl transferase
transferase inhibiting
quinoline enantiomer
annelated quinoline
Prior art date
Application number
MYPI20012896A
Other languages
English (en)
Inventor
Venet Marc Gaston
Angibaud Patrick Ren Xc
End David William
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MY127734A publication Critical patent/MY127734A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI20012896A 2000-06-22 2001-06-20 Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer MY127734A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22

Publications (1)

Publication Number Publication Date
MY127734A true MY127734A (en) 2006-12-29

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20012896A MY127734A (en) 2000-06-22 2001-06-20 Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Country Status (33)

Country Link
US (3) US20030114471A1 (OSRAM)
EP (1) EP1296984B1 (OSRAM)
JP (1) JP4919575B2 (OSRAM)
KR (2) KR100846370B1 (OSRAM)
CN (1) CN1207296C (OSRAM)
AR (1) AR030704A1 (OSRAM)
AT (1) ATE294804T1 (OSRAM)
AU (3) AU2001263962B2 (OSRAM)
BG (1) BG65894B1 (OSRAM)
BR (1) BRPI0111743B8 (OSRAM)
CA (1) CA2410232C (OSRAM)
CZ (1) CZ295278B6 (OSRAM)
DE (1) DE60110592T2 (OSRAM)
EA (1) EA005065B1 (OSRAM)
EE (1) EE04966B1 (OSRAM)
EG (1) EG24180A (OSRAM)
ES (1) ES2241830T3 (OSRAM)
HR (1) HRP20020989B1 (OSRAM)
HU (1) HU229095B1 (OSRAM)
IL (2) IL153560A0 (OSRAM)
IS (1) IS2596B (OSRAM)
JO (1) JO2361B1 (OSRAM)
MX (1) MXPA02012845A (OSRAM)
MY (1) MY127734A (OSRAM)
NO (1) NO324494B1 (OSRAM)
NZ (1) NZ522481A (OSRAM)
PA (1) PA8519501A1 (OSRAM)
PL (1) PL209521B1 (OSRAM)
SA (1) SA01220349B1 (OSRAM)
SK (1) SK285699B6 (OSRAM)
UA (1) UA73572C2 (OSRAM)
WO (1) WO2001098302A1 (OSRAM)
ZA (1) ZA200210305B (OSRAM)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
WO2016090107A2 (en) * 2014-12-04 2016-06-09 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
ES2844848T3 (es) 2015-04-21 2021-07-22 Eiger Biopharmaceuticals Inc Composiciones farmacéuticas que comprenden Lonafarnib y Ritonavir
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
EP3838275A1 (en) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase inhibitors for use in methods of treating cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SI0865440T1 (en) * 1995-12-08 2002-08-31 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6177432B1 (en) * 1997-04-25 2001-01-23 Janssen-Cilag S.A. Farnesyltransferase inhibiting quinazolinones
IL133212A (en) 1997-06-02 2005-12-18 Janssen Pharmaceutica Nv History of use (imidazolil-5-yl) methyl-2-quinolinone that act as culture inhibitors of smooth muscle cells
BR9911861A (pt) * 1998-07-06 2001-03-20 Janssen Pharmaceutica Nv Inibidores de farnesil proteìna transferase com as propriedades radiossensibilizadoras in vivo
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000012499A1 (en) * 1998-08-27 2000-03-09 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
SI1140935T1 (en) * 1998-12-23 2003-10-31 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
HK1042096A1 (zh) * 1999-02-11 2002-08-02 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de) * 2000-02-24 2007-11-15 Janssen Pharmaceutica Nv Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
US7196094B2 (en) 2000-09-25 2007-03-27 Janssen Pharmaceutica, N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体

Also Published As

Publication number Publication date
BRPI0111743B1 (pt) 2019-03-26
IS6590A (is) 2002-10-25
AU6396201A (en) 2002-01-02
CZ2003114A3 (cs) 2003-05-14
JO2361B1 (en) 2006-12-12
NO20026032D0 (no) 2002-12-16
US8318753B2 (en) 2012-11-27
EP1296984A1 (en) 2003-04-02
BR0111743A (pt) 2003-07-08
EA005065B1 (ru) 2004-10-28
DE60110592D1 (de) 2005-06-09
JP2004501153A (ja) 2004-01-15
WO2001098302A1 (en) 2001-12-27
HK1058363A1 (en) 2004-05-14
US20070259902A1 (en) 2007-11-08
PL209521B1 (pl) 2011-09-30
CA2410232A1 (en) 2001-12-27
AU2001263962B2 (en) 2006-07-20
IL153560A0 (en) 2003-07-06
IS2596B (is) 2010-03-15
AR030704A1 (es) 2003-09-03
ZA200210305B (en) 2004-03-19
ES2241830T3 (es) 2005-11-01
EE200200695A (et) 2004-06-15
PL358918A1 (en) 2004-08-23
HRP20020989A2 (en) 2005-02-28
HUP0300872A2 (hu) 2003-07-28
HU229095B1 (en) 2013-07-29
KR20030009463A (ko) 2003-01-29
IL153560A (en) 2011-06-30
US20080114009A1 (en) 2008-05-15
SA01220349B1 (ar) 2007-01-23
HUP0300872A3 (en) 2004-11-29
ATE294804T1 (de) 2005-05-15
SK285699B6 (sk) 2007-06-07
BG107310A (bg) 2003-07-31
SK502003A3 (en) 2003-05-02
HRP20020989B1 (hr) 2011-05-31
US20030114471A1 (en) 2003-06-19
EG24180A (en) 2008-09-28
AU2006220405A1 (en) 2006-10-12
MXPA02012845A (es) 2003-05-15
KR100846370B1 (ko) 2008-07-15
AU2006220405B2 (en) 2009-05-21
US8329714B2 (en) 2012-12-11
NO324494B1 (no) 2007-10-29
EE04966B1 (et) 2008-02-15
UA73572C2 (en) 2005-08-15
PA8519501A1 (es) 2002-08-29
BRPI0111743B8 (pt) 2021-05-25
JP4919575B2 (ja) 2012-04-18
BG65894B1 (bg) 2010-04-30
KR100831940B1 (ko) 2008-05-23
NZ522481A (en) 2004-09-24
EP1296984B1 (en) 2005-05-04
CN1207296C (zh) 2005-06-22
NO20026032L (no) 2002-12-16
EA200300048A1 (ru) 2003-04-24
KR20070121847A (ko) 2007-12-27
DE60110592T2 (de) 2006-01-19
CZ295278B6 (cs) 2005-06-15
CA2410232C (en) 2008-10-07
CN1437601A (zh) 2003-08-20

Similar Documents

Publication Publication Date Title
GEP20053530B (en) Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
GEP20043324B (en) Purine Derivatives
HUP0202319A3 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
WO2003000695A8 (en) Pyrrolopyrimidines as protein kinase inhibitors
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
IL162294A0 (en) Formulation & dosage form for the controlled delivery of therapeutic agents
AU7031500A (en) Therapeutic quinazoline compounds
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
HK1042303A1 (zh) 新的化合物
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
MY127734A (en) Pharmaceutical compositions comprising a farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
IL151553A0 (en) Orally administered controlled delivery system for once daily administration of ciprofloxacin
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
HK1042493A1 (zh) 新的化合物
MY122477A (en) Sertraline oral concentrate
MY133438A (en) Morpholinobenzamide salts
YU25202A (sh) Supstituisani piroli kao antiproliferativna sredstva za lečenje kancera
HU0500745D0 (en) Rapidly decomposable pharmaceutical dosage form for use in oral or body cavity containing nicotine as active ingredient